Dr. Reddy's Launches First-to-Market Generic of Extra-Strength Pataday® in U.S. OTC Market
RDY is trading near its 52-week low of $12.26 (8.5% above the low).
Summary
Dr. Reddy's Laboratories announced the first-to-market U.S. launch of a generic equivalent to Extra-Strength Pataday® Once Daily Relief, expanding its OTC eye-care portfolio.
Key Events · Product Development and Regulatory · RDY
-
First-to-Market Generic Launch
Dr. Reddy's launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
-
Market Opportunity
The branded Pataday® product had U.S. sales of approximately $69.9 million in the latest 52-week period, representing a significant market for the new generic.
-
Portfolio Expansion
This launch strengthens Dr. Reddy's existing OTC eye-care portfolio, which already includes 0.2% and 0.1% strengths of Olopatadine Hydrochloride Ophthalmic Solution.
Analysis · RDY · Life Sciences
This launch expands Dr. Reddy's presence in the U.S. over-the-counter eye-care market with a key generic product. Being the first to market for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% provides a significant competitive advantage, allowing the company to capture a substantial share of the approximately $69.9 million annual sales market for the branded product. This demonstrates Dr. Reddy's strong capabilities in generic product development and commercialization.
At the time of this filing, RDY was trading at $13.30 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11B. The 52-week trading range was $12.26 to $16.17. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.